Labetalol to Prevent Hypertension and Tachycardia During Fiberoptic Bronchoscopy

This study has been completed.
Sponsor:
Information provided by:
Rabin Medical Center
ClinicalTrials.gov Identifier:
NCT00394537
First received: October 31, 2006
Last updated: June 4, 2007
Last verified: May 2007

October 31, 2006
June 4, 2007
Not Provided
Not Provided
  • Heart Rate
  • Systolic Blood Pressure
  • Diastolic Blood Pressure
  • Rate pressure product (HR*SBP/100)
Same as current
Complete list of historical versions of study NCT00394537 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Labetalol to Prevent Hypertension and Tachycardia During Fiberoptic Bronchoscopy
Not Provided

Passing a bronchoscope through the airways frequently causes a stress response even though patients are sedated. This stress response is usually an increase in pulse and blood pressure, which may have undesirable effects on the heart and circulation.

We plan to give patients labetalol (a beta blocker which reduces pulse and blood pressure) in addition to normal sedation, to patients undergoing bronchoscopy in our department.

Not Provided
Interventional
Phase 4
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Bronchoscopy
Drug: Labetalol 10mg iv
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
72
May 2007
Not Provided

Inclusion Criteria:

  • All patients over 18 years old undergo fiberoptic bronchoscopy in our unit

Exclusion Criteria:

  • inability or refusal to give informed consent
  • bronchoscopy through an artificial airway
  • intolerance or allergy to the study drug
  • bradycardia (HR<60/min) or hypotension (systolic BP <100) at screening
  • pregnancy,
  • concomitant treatment with diltiazem or verapamil
  • intention to use propofol as the sedative agent for bronchoscopy.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Israel
 
NCT00394537
3997
Not Provided
Not Provided
Rabin Medical Center
Not Provided
Principal Investigator: Mordechai Kramer, MD Rabin Medical Center
Rabin Medical Center
May 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP